F2G Ltd, the UK-based antifungal drug discovery and development company, has announced the publication of the initial F901318 data in the prestigious scientific journal Proceedings of the National Academy of Sciences (PNAS), of their work in elucidating the mechanism of action of its novel orotomide antifungal – lead candidate F901318. The study entitled “F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase” can be found here: http://www.pnas.org/content/early/2016/10/24/1608304113.abstract.
Anders Hinsby, CEO of Orphazyme ApS, says: “The whole team at Orphazyme has been working tirelessly to bring our technology and scientific advancements from the laboratory into the clinic. With Thomas Blaettler now on board, we will be well equipped to design and implement long-term clinical strategies, fulfilling our aim to improve the lives of those suffering with rare, and often fatal, diseases.”
A new treatment for a currently incurable group of inherited neurological diseases that affect 1 in 10000 children has been revealed, which works by triggering the body’s own ‘recycling’ system. New research by scientists at Orphazyme ApS, published in Science Translational Medicine, reveals a promising method to treat several diseases in the sphingolipidoses family of lysosomal storage diseases. These debilitating disorders, including Niemann-Pick type C, Fabry, and Sandhoff diseases, involve the accumulation of sphingolipids (fat molecules) in the cells and are often fatal during early childhood.
Sunstone Life Science Fund III portfolio company Rigontec, the leader in RIG-I targeting RNA therapeutics, has announced that it has secured EUR 15 million in a third and final closing of its Series A round. The financing represents additional capital from current investors Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds (HTGF), NRW.BANK, MP Healthcare Venture Management, Sunstone Capital and Wellington Partners Life Sciences. The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic.
Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Matthias Schroff, PhD, as Chief Executive Officer (CEO).
Dr. Schroff has over fifteen years of experience in the biotechnology industry. Previously, he was CEO of Mologen AG, a publicly traded German biotech company, serving on the company’s executive board for over ten years. In the eight years that Dr. Schroff served as CEO, he built Mologen from an early preclinical stage to an established immuno-oncology company with programs in Phase 2 and 3 clinical trials. In addition to his position at Mologen, Dr. Schroff served on the Board of Directors of the biotech arm of the Association of Research-based Pharmaceutical Companies (vfA bio). During his career, Dr. Schroff has served in a variety of functions, including research, manufacturing, scientific collaborations, for example with the MD Anderson Cancer Center, clinical development, business development and investor relations. He is the inventor of numerous patents in the field of immuno-oncology, RNAi and gene expression, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications. Dr. Schroff received his PhD in biochemistry from Freie Universität Berlin at the Institute of Molecular Biology and Biochemistry, where he was involved in clinical trials in immunotherapy against cancer as early as 1994.